PRESSING Need of Precision Care in HER2-Positive Colorectal Cancer: The ELEPHANT in the Room

Kanwal P.S. Raghav; Jonathan Michael Loree; Scott Kopetz

doi:10.1158/1078-0432.CCR-23-2580

PRESSING Need of Precision Care in HER2-Positive Colorectal Cancer: The ELEPHANT in the Room

Kanwal P.S. Raghav, Jonathan Michael Loree, Scott Kopetz

GI Medical Oncology

Research output: Contribution to journal › Article › peer-review

Abstract

Although dual HER2 inhibition has shown promising clinical activity in patients with RAS wild-type HER2-positive metastatic colorectal cancer, predictive biomarkers of response/resistance are less well characterized.

Original language	English (US)
Pages (from-to)	260-262
Number of pages	3
Journal	Clinical Cancer Research
Volume	30
Issue number	2
DOIs	https://doi.org/10.1158/1078-0432.CCR-23-2580
State	Published - Jan 15 2024

ASJC Scopus subject areas

General Medicine

Access to Document

10.1158/1078-0432.CCR-23-2580

Cite this

@article{083de438be31473c9610faf5474ba05a,

title = "PRESSING Need of Precision Care in HER2-Positive Colorectal Cancer: The ELEPHANT in the Room",

abstract = "Although dual HER2 inhibition has shown promising clinical activity in patients with RAS wild-type HER2-positive metastatic colorectal cancer, predictive biomarkers of response/resistance are less well characterized.",

author = "Raghav, {Kanwal P.S.} and Loree, {Jonathan Michael} and Scott Kopetz",

note = "Publisher Copyright: {\textcopyright} 2023 American Association for Cancer Research.",

year = "2024",

month = jan,

day = "15",

doi = "10.1158/1078-0432.CCR-23-2580",

language = "English (US)",

volume = "30",

pages = "260--262",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "2",

}

TY - JOUR

T1 - PRESSING Need of Precision Care in HER2-Positive Colorectal Cancer

T2 - The ELEPHANT in the Room

AU - Raghav, Kanwal P.S.

AU - Loree, Jonathan Michael

AU - Kopetz, Scott

PY - 2024/1/15

Y1 - 2024/1/15

N2 - Although dual HER2 inhibition has shown promising clinical activity in patients with RAS wild-type HER2-positive metastatic colorectal cancer, predictive biomarkers of response/resistance are less well characterized.

AB - Although dual HER2 inhibition has shown promising clinical activity in patients with RAS wild-type HER2-positive metastatic colorectal cancer, predictive biomarkers of response/resistance are less well characterized.

UR - http://www.scopus.com/inward/record.url?scp=85182732231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85182732231&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-23-2580

DO - 10.1158/1078-0432.CCR-23-2580

M3 - Article

C2 - 37975903

AN - SCOPUS:85182732231

SN - 1078-0432

VL - 30

SP - 260

EP - 262

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 2

ER -

PRESSING Need of Precision Care in HER2-Positive Colorectal Cancer: The ELEPHANT in the Room

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this